Sai Life Sciences Limited

BSE: SAILIFE544306ISIN INE570L01029

Healthcare
Pharmaceuticals
BSE 500

Share price

₹1,546.30-10.65 (-0.68%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹1,697.00
52W low: ₹786.15
Off 52W high: -8.88%
1M return: +2.29%
3M return: +10.98%
6M return: +43.38%
1Y return: +67.49%
20D avg volume: 56,330
50 DMA: ₹1,520.57
200 DMA: ₹1,205.17

Key ratios Consolidated

Market cap: ₹32,855 Cr
Current price: ₹1,546.30
52W high / low: ₹1,697.00 / ₹786.15
Face value: ₹1.00
P/E: 90.80
P/B: 13.19
EPS (TTM): ₹17.03
Book value / share: ₹117.28
ROE: —
ROCE: 18.10%
Operating margin: —
Net margin: —
Debt / equity: 0.04
Net debt: ₹13.21 Cr
Interest cover: 12.88
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 39.8 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q4 FY24
Income statement
	554.28	602.14	556.46	537.47	496.42	579.51	439.78	—
	3.54	15.52	8.38	15.32	9.90	9.60	9.12	—
	557.83	617.66	564.84	552.79	506.32	589.11	448.89	—
	459.85	478.72	422.38	440.74	425.57	470.31	377.25	—
	177.85	159.19	114.24	203.53	159.50	156.87	121.53	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—
	179.90	186.65	172.99	162.79	160.62	151.09	132.94	—
	7.64	7.83	9.70	9.35	12.36	10.89	23.13	—
	45.94	45.31	44.08	39.75	37.72	37.49	34.09	—
	81.47	77.23	67.67	88.73	73.76	103.12	66.26	—
	97.97	138.94	142.46	112.05	80.75	118.80	71.65	—
	0.00	0.29	-8.29	0.00	0.00	0.00	0.00	—
	97.97	139.23	134.17	112.05	80.75	118.80	71.65	—
	24.69	34.99	33.79	28.21	20.29	30.53	17.80	—
	73.28	104.24	100.38	83.84	60.45	88.27	53.85	—
	3.46	4.93	4.77	4.01	2.90	4.24	2.89	—
Key metrics
	151.55	192.37	187.95	161.15	130.83	167.18	128.87	—
	27.30%	31.90%	33.80%	30.00%	26.40%	28.80%	29.30%	—
	13.20%	17.30%	18.00%	15.60%	12.20%	15.20%	12.20%	—
	—	5.30%	—	4.70%	—	5.30%	—	—
	11.70%	3.90%	26.50%	—	—	—	—	—
	21.20%	18.10%	86.40%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	2,250	2,192	1,695	—
	42.76	49.13	36.78	—
	2,293	2,242	1,731	—
	1,802	1,767	1,504	—
	654.81	578.12	460.80	—
	0.00	0.00	0.00	—
	702.33	683.05	549.12	—
	34.52	39.24	76.16	—
	175.08	166.85	138.57	—
	315.10	307.39	274.03	—
	491.42	474.19	227.70	—
	-8.00	-8.00	0.00	—
	483.42	466.19	227.70	—
	121.68	117.28	57.57	—
	361.74	348.91	170.13	—
	17.17	16.63	8.83	—
Key metrics
	693.02	672.28	442.43	—
	30.80%	30.70%	26.10%	—
	16.07%	15.90%	10.00%	—
	—	18.10%	12.50%	—
	—	29.40%	—	—
	—	105.10%	—	—
	—	-83.83	-55.23	—
	—	1.46	1.85	—
	—	0.04	0.06	—
	—	13.21	37.52	—
	—	39.8	32.5	—
Balance sheet
	—	3,626	3,160	—
	—	1,411	1,505	—
	—	81.91	91.12	—
	—	373.62	354.78	—
	—	150.97	118.86	—
	—	624.11	487.36	—
	—	1,809	1,477	—
	—	285.34	322.51	—
	—	833.68	732.49	—
	—	95.12	128.64	—
	—	74.62	128.64	—
	—	20.50	0.00	—
	—	2,484	2,128	—
Cash flow
	—	509.13	314.05	—
	—	-395.41	-536.66	—
	—	-123.68	301.43	—
	—	592.96	369.28	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q4 FY24
Income statement
	546.73	594.34	549.18	526.67	483.04	567.01	428.60	—
	3.54	15.74	8.45	14.93	10.01	9.82	9.45	—
	550.27	610.09	557.63	541.60	493.04	576.83	438.05	—
	454.94	473.53	418.86	430.73	415.06	456.36	370.14	—
	175.57	158.48	112.76	141.78	155.33	154.06	116.92	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—
	161.68	169.88	159.23	146.04	142.59	134.55	121.06	—
	5.98	6.16	8.06	7.70	10.70	9.16	21.66	—
	42.13	41.16	40.60	36.21	34.33	34.09	31.07	—
	102.52	95.85	84.44	104.38	90.27	114.16	79.69	—
	95.33	136.56	138.76	110.87	77.98	120.47	67.91	—
	0.00	0.29	-8.29	0.00	0.00	0.00	—	—
	95.33	136.85	130.47	110.87	77.98	120.47	67.91	—
	24.00	34.32	32.84	27.92	19.61	30.53	16.86	—
	71.34	102.53	97.63	82.95	58.37	89.94	51.06	—
	3.36	4.85	4.64	3.97	2.80	4.32	2.74	—
Key metrics
	143.44	184.17	179.13	154.78	123.01	163.72	120.64	—
	26.20%	31.00%	32.60%	29.40%	25.50%	28.90%	28.10%	—
	13.00%	17.30%	17.80%	15.70%	12.10%	15.90%	11.90%	—
	—	5.20%	—	4.70%	—	5.40%	—	—
	13.20%	4.80%	28.10%	—	—	—	—	—
	22.20%	14.00%	91.20%	—	—	—	—	—

Metric	TTM	FY26	FY25	FY24
Income statement
	2,217	2,153	1,642	—
	42.66	49.13	37.34	—
	2,260	2,202	1,679	—
	1,778	1,738	1,448	—
	588.59	568.34	445.52	—
	0.00	0.00	0.00	—
	636.83	617.73	485.56	—
	27.90	32.62	70.03	—
	160.10	152.30	126.03	—
	387.19	374.95	316.40	—
	481.52	464.17	231.72	—
	-8.00	-8.00	0.00	—
	473.52	456.17	231.72	—
	119.08	114.69	58.25	—
	354.45	341.48	173.46	—
	16.82	16.27	9.00	—
Key metrics
	661.52	641.09	427.78	—
	29.84%	29.80%	26.10%	—
	15.99%	15.90%	10.60%	—
	—	17.70%	12.50%	—
	—	31.10%	—	—
	—	96.90%	—	—
	—	-94.99	-33.14	—
	—	1.45	1.90	—
	—	0.04	0.06	—
	—	16.52	43.45	—
	—	36.1	30.8	—
Balance sheet
	—	3,603	3,137	—
	—	1,399	1,495	—
	—	78.60	85.19	—
	—	369.71	352.87	—
	—	149.90	118.33	—
	—	621.00	485.76	—
	—	1,699	1,367	—
	—	306.93	332.65	—
	—	842.26	727.20	—
	—	95.12	128.64	—
	—	74.62	128.64	—
	—	20.50	0.00	—
	—	2,508	2,167	—
Cash flow
	—	495.27	330.35	—
	—	-392.71	-564.71	—
	—	-109.22	314.31	—
	—	590.26	363.49	—

Compounded growth

Standalone

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 34.51%

Quarter	September 2026	June 2026
Promoter %	34.51%	34.53%

Holder	Type	Holding	Previous	Change
MYTREYI KANUMURI Partner of Marigold Partners (Partnership Firm)	Promoter	10.44%	10.45%	-0.01%
INVESCO INDIA FLEXI CAP FUND	Public	7.43%	—	—
RANGA RAJU KANUMURI Partner of Sunflower Partners (Partnership Firm)	Promoter	7.34%	7.35%	-0.01%
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA MUL	Public	6.79%	—	—
GOKARAJU SUBBA RAJU	Promoter Group	4.54%	4.54%	0.00%
MYTREYI KANUMURI Partner of Tulip Partners (Partnership Firm)	Promoter	4.37%	4.37%	0.00%
RANGA RAJU KANUMURI Partner of Lily Partners (Partnership Firm)	Promoter	3.25%	3.25%	0.00%
AXIS MUTUAL FUND TRUSTEE LIMITED A/C AXIS MUTUAL F	Public	3.19%	2.90%	+0.29%
ADITYA BIRLA SUN LIFE MUTUAL FUND - ADITYA BIRLA S	Public	2.81%	—	—
SMALLCAP WORLD FUND, INC	Public	2.57%	2.57%	0.00%
SAI QUEST SYN PRIVATE LIMITED	Promoter	2.16%	2.16%	0.00%
HSBC MUTUAL FUND - HSBC AGGRESSIVE HYBRID FUND	Public	1.86%	1.86%	0.00%
AXIS MAX LIFE INSURANCE LIMITED A/C - ULIF00525/11	Public	1.52%	—	—
KRISHNAM RAJU KANUMURI	Promoter	1.42%	1.42%	0.00%
GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY P	Public	1.18%	1.23%	-0.05%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%

Filings & corporate actions

Recent announcements

Earnings Call details for unaudited financial results for the second quarter and half year ended 30th September 2026.19 Oct 2026 · Company Update / Analyst / Investor Meet
Allotment of 54,500 Equity Shares having Face Value of Rs. 1/- each, as per Companies ESOP Plan12 Oct 2026 · Company Update / Allotment of ESOP / ESPS
Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018 for the quarter ended 30th September 2026.5 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Sai Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve unaudited financial results ....1 Oct 2026 · Board Meeting / Board Meeting
Closure of Trading Window relating to Unaudited Financial Result for the Second Quarter and Half Year Ending on 30th September 202628 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Allotment of 24,000 Equity Shares having Face Value of Rs. 1/- as per Company''s ESOP Plan18 Sep 2026 · Company Update / Allotment of ESOP / ESPS
Voting Results and Scrutinizer''s Report of 27th Annual General Meeting (AGM) of the Company17 Sep 2026 · AGM/EGM / AGM
Proceedings of 27th Annual General Meeting (AGM) of the Company17 Sep 2026 · AGM/EGM / AGM
Investors Conference - 18th September 20264 Sep 2026 · Company Update / Analyst / Investor Meet
Investors Conference - 14th September 20264 Sep 2026 · Company Update / Analyst / Investor Meet
Allotment of 80,600 Equity shares having Face Value ?1/- each as per Company''s ESOP Plans1 Sep 2026 · Company Update / Allotment of ESOP / ESPS
Newspaper Publication relating to 27th AGM (Post-dispatch Advt.)26 Aug 2026 · Company Update / Newspaper Publication
Please refer the attachment25 Aug 2026 · Company Update / General
Business Responsibility and Sustainability Report (BRSR) and ESG Databook of Sai Life Sciences Limited for the FY 2025-2625 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Integrated Annual Report of Sai Life Sciences Limited for the FY 2025-2625 Aug 2026 · Others / Reg. 34 (1) Annual Report
Notice of 27th Annual General Meeting (AGM) of the Company25 Aug 2026 · AGM/EGM / AGM
Newspaper Publication relating to 27th AGM (Pre-dispatch Advt.)24 Aug 2026 · Company Update / Newspaper Publication
Information relating to 27th Annual General Meeting (AGM) and Cut-off date for e-voting.24 Aug 2026 · AGM/EGM / AGM
Transcript of Earnings Conference Call organised on 07 August 202612 Aug 2026 · Company Update / Earnings Call Transcript
Newspaper publication for Un-audited Financial Results of the Company for the quarter ended on 30 June 20268 Aug 2026 · Company Update / Newspaper Publication
Monitoring Agency Report for the Quarter ended on 30 June 20267 Aug 2026 · Company Update / Monitoring Agency Report
Recording of Earnings Call for the Unaudited Financial Results of the Company for the quarter ended on 30 June 2026.7 Aug 2026 · Company Update / Analyst / Investor Meet
Investor Presentation for the quarter ended on 30 June 20267 Aug 2026 · Company Update / Investor Presentation
Allotment of 18,700 equity shares under Employee Stock Option Plan6 Aug 2026 · Company Update / Allotment of Equity Shares
Press Release for the Unaudited financial results for the quarter ended 30 June 20266 Aug 2026 · Company Update / Press Release / Media Release
Unaudited Financial results (Standalone and Consolidate) for the Quarter ended on 30 June 20266 Aug 2026 · Result / Financial Results
Board Meeting Outcome for Approval of Unaudited Financial Results (Standalone and Consolidated) For the Quarter Ended On 30 June 20266 Aug 2026 · Board Meeting / Outcome of Board Meeting
Analyst/Investor Meet on 13 August 2026 and 14 August 2026 at Singapore4 Aug 2026 · Company Update / Analyst / Investor Meet
Earnings Conference call Invite to discuss Un-audited Financial Results of the Company for the Quarter ended 30 June 2026.30 Jul 2026 · Company Update / Analyst / Investor Meet
Allotment of 8,900 Equity Shares under ESOP 2008 Scheme of the Company10 Jul 2026 · Company Update / Allotment of Equity Shares
Please refer to enclosed Intimation7 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Sai Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve Un-audited Financial Results ....1 Jul 2026 · Board Meeting / Board Meeting
Trading Window Closure Intimation25 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Allotment of 1,70,501 Equity Shares under ESOP schemes of the Company.22 Jun 2026 · Company Update / Allotment of Equity Shares
Analyst/Investor Meet on 11 June 2026 at Hyderabad10 Jun 2026 · Company Update / Analyst / Investor Meet
Intimation of schedule of meeting with analyst / Investor on 3rd and 4th June 2026 at Mumbai.27 May 2026 · Company Update / Analyst / Investor Meet
Transcript of Earnings Call for the Audited Financial Results for the quarter and year ended 31 March 2026.21 May 2026 · Company Update / Earnings Call Transcript
Newspaper publication for the Audited Financial Results for the quarter and year ended 31 March 2026.16 May 2026 · Company Update / Newspaper Publication
Recording of Earnings Call for the Audited Financial Results for the quarter and year ended 31 March 2026.15 May 2026 · Company Update / Analyst / Investor Meet
Allotment of 92,000 Equity Shares under ESOP Schemes of the Company.15 May 2026 · Company Update / Allotment of ESOP / ESPS

Board meetings

5 Nov 2026 Board Meeting - Financial Results
6 Aug 2026 Board Meeting - Financial Results